ArticleRegenerative biomaterials2026
Integrated platform for EV separation and controlled release based on gelatin microspheres for diabetic wound treatment.
Article in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic wounds exhibit impaired healing owing to multiple pathological factors and current treatment options remain limited, underscoring the urgent need for novel therapeutic strategies. Extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) are emerging as promising candidates for wound healing. However, the process from isolation to application of EVs is complex and time-consuming, which probably influences the activity and the therapeutic effects of EVs. To address these issues, we created the integrated platform for EV separation and controlled release. Gelatin microspheres (GMS) were prepared and functionalized with the variable domain of heavy-chain-only antibodies (GMS-VHH). GMS-VHH enabled the efficient capture of CD9-positive EVs in the culture supernatant of MSCs, forming EVs-loaded gelatin microspheres (GMS@EVs). The characterization of EVs demonstrated that the GMS-VHH isolation method outperformed traditional ultracentrifugation in terms of EV structural integrity. GMS@EVs exhibited excellent biocompatibility and promoted the proliferation of epidermal keratinocytes
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.